Bioretec Oy (HEL:BRETEC)

Finland flag Finland · Delayed Price · Currency is EUR
0.0246
+0.0072 (41.38%)
At close: May 18, 2026
Market Cap33.01M -37.8%
Revenuen/a
Net Incomen/a
EPSn/a
Shares Out1.34B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,831,899
Average Volume3,949,896
Open0.0190
Previous Close0.0174
Day's Range0.0182 - 0.0260
52-Week Range0.0108 - 2.3200
Beta0.54
RSI29.26
Earnings DateMay 15, 2026

About Bioretec Oy

Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatmen... [Read more]

Sector Healthcare
Founded 1998
Country Finland
Stock Exchange Nasdaq Helsinki
Ticker Symbol BRETEC
Full Company Profile

News

Bioretec Oy Earnings Call Transcript: Q4 2025

2025 was a transformative year with leadership changes, strategic resets, and strong regulatory wins. U.S. direct sales grew over 60% quarter-over-quarter, but total revenue dipped due to distribution model changes and one-off items. Focus remains on commercial growth and capital strengthening.

3 months ago - Transcripts

Bioretec Ltd (OHEL:BRETEC) Q4 2025 Earnings Report Preview: What To Expect

Bioretec Ltd (OHEL:BRETEC) Q4 2025 Earnings Report Preview: What To Expect

3 months ago - GuruFocus

Bioretec Board Approves Updated Strategy, Financial Targets For 2026-2028 Period

(RTTNews) - Bioretec (0TN.F, BRETEC.HE) said Board of Directors has approved the company's updated strategy for 2026-2028 and new financial targets for the strategy period. Bioretec's new financial ta...

5 months ago - Nasdaq

Bioretec Secures FDA Breakthrough Device Designation For RemeOs DrillPin

(RTTNews) - Bioretec Oy (0TN.F, BRETEC.HE) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magnesium alloy technology-based, biodegradable RemeO...

5 months ago - Nasdaq

Bioretec Ltd's business review Q1 2025: Strong net sales in the first quarter; CE approval with comprehensive indications received in January accelerates the future expansion of RemeOs products

Bioretec Ltd Company announcement 15 May 2025 at 8:00 a.m. TAMPERE, Finland , May 15, 2025 /PRNewswire/ -- This announcement summarizes Bioretec Ltd's business review for January- March 2025 . The com...

1 year ago - Benzinga